20th Mar 2018 09:51
According to the US Food & Drug Administration product approval letter, West-Ward is eligible for 180 days of generic drug exclusivity.
West-Ward's Ritonavir is approved by FDA for use in combination with other antiretroviral agents for treatment of the human immunodeficiency virus HIV-1 infection.
West-Ward understands that this is a very unique market that requires special consideration, Hikma said. It is engaging with advocacy groups to better understand how to communicate and support patients and healthcare providers.
Hikma's subsidiary is also launching an education and awareness campaign, including a website and direct communication.
"We are very excited to be launching Ritonavir Tablets USP. This is an exciting product which demonstrates the successful execution of our strategy to develop differentiated products. We will be launching ritonavir with additional patient support and co-pay assistance to ensure more people are able to access this life-saving medicine," said Hikma Generics Division President Brian Hoffmann.
Hikma shares were down 1.5% at
Related Shares:
Hikma Pharmaceuticals